Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma

Published:2021-12-08 Issue:2 Volume:26 Page:436-448
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Song Xuming¹²³⁴,Chen Qiang⁵,Wang Jifan¹²³⁴,Mao Qixing¹²³,Xia Wenjie¹²³,Xu Lin¹²³⁴,Jiang Feng¹²³⁴,Dong Gaochao¹³^ORCID

Affiliation:

1. The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China

2. Department of Thoracic Surgery Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing China

3. Jiangsu Key Laboratory of Molecular and Translational Cancer Research Cancer Institute of Jiangsu Province Nanjing China

4. The Fourth Clinical College of Nanjing Medical University Nanjing China

5. XuZhou Central Hospital Xuzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17097

Reference55 articles.

1. The 2015 World Health Organization Classification of Lung Tumors

2. Immunotherapy and tumor microenvironment

3. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a combined ferroptosis and immune prognostic signature for lung adenocarcinoma;Translational Cancer Research;2022-10

2. P2RY14 downregulation in lung adenocarcinoma: a potential therapeutic target associated with immune infiltration;Journal of Thoracic Disease;2022-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3